Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Champix

This page shows the latest Champix news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects

Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects

They also found that smokers treated with Champix had significantly higher quit rates than those treated with Zyban, nicotine patch or placebo. ... For Pfizer, the results provide an opportunity for Champix to start building sales momentum that stalled

Latest news

  • Study clears Pfizer’s Champix of serious risks Study clears Pfizer’s Champix of serious risks

    New research indicates Pfizer's stop-smoking drug Champix may not increase the risk of depression and heart attacks as previously thought. ... Additionally, use of Champix was associated with a significantly reduced risk of ischaemic heart disease,

  • PMEA 2009: Winners announced

    Company: AstraZeneca UK. Finalist:. Title of Entry: Champix UK Team. Company: Pfizer UK. Finalist:. ... Company: Schering-Plough.  . Sponsored by:Chandler Chicco Companies. Winner:. Title of Entry: CHAMPIX European Brand Team.

  • Data shows positive results for Champix

    Smokers who took Pfizer's Champix were more successful in quitting smoking and abstaining compared with those taking a placebo. ... Results from a new study show smokers who took Pfizer's Champix (varenicline) were 33.5 per cent more successful in

  • FDA boxed warnings for Chantix and Zyban

    The US Food and Drug Administration (FDA) has announced a requirement for Pfizer and GlaxoSmithKline to put a boxed warning on the prescribing information for their smoking cessation drugs Chantix (Champix

  • PMEA 2008: Results and winners and pictures

    Product Launch of the Year. Sponsored by Medicom. Winner. Champix.

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • On our best behaviour On our best behaviour

    Meanwhile, for non-nicotine pharmacotherapies with proven efficacy, such as Pfizer’s Champix (varenicline), their impact on effecting behaviour change depends almost entirely on reimbursement. ... In the UK, for example, Champix peaked at 200, 000

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...

Quick links